AdamScottKittaiMDMD(He/Him)

Hematologic Oncology

Assistant Professor

Dr. Kittai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2016 - 2019
George Washington UniversityChief Residency, Internal Medicine, 2015 - 2016
George Washington UniversityResidency, Internal Medicine, 2012 - 2015
Tel Aviv University SacklerClass of 2012

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia Start of enrollment: 2022 Sep 13
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome Start of enrollment: 2023 Jul 28
Recruiting
Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator

PubMed

11 citations
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation.
Sunnia T Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer
Journal of Hematology & Oncology. 2022-07-14
33 citations
Ventricular arrhythmias and sudden death events following acalabrutinib initiation.
Seema A Bhat, John Gambril, Leylah Azali, Sunnia T Chen, Lindsay Rosen
Blood. 2022-11-17
32 citations
Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells
Scott R Best, Taylor Hashiguchi, Adam Kittai, Nur Bruss, Cody Paiva
Blood Advances. 2019-01-08

Abstracts/Posters

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies
Adam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
Adam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
Adam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

$A Matching-Adjusted Indirect Comparison (MAIC) of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia$
A Matching-Adjusted Indirect Comparison (MAIC) of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJuly 30th, 2024
Efficacy of New Agents, CAR-T Insights Among EHA 2024 Highlights in CLLJuly 12th, 2024
$BTK Degrader Shows Potential for Treating Refractory CLL and SLL$
BTK Degrader Shows Potential for Treating Refractory CLL and SLLFebruary 8th, 2023
Join now to see all